Adaptive COVID-19 drug combo trial wraps up
NCT ID NCT05077332
First seen Jan 05, 2026 · Last updated May 24, 2026 · Updated 18 times
Summary
This completed Phase 2 trial tested the safety and effectiveness of different drug combinations in people with COVID-19. It used a master protocol that allowed both hospitalized and non-hospitalized patients to join. Only 4 participants were enrolled, and the study focused on measuring recovery time and death rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
US02-04: Integrated Health Solutions
Miami, Florida, 33126, United States
Conditions
Explore the condition pages connected to this study.